Nail Psoriasis Treatment 2026: Signs, Diagnosis & Options | Podiatrist

Nail psoriasis is one of the most underdiagnosed and undertreated conditions we see in podiatric practice. Patients come to us having spent years using antifungal treatments that never worked — because the problem was never fungal in the first place. Nail psoriasis has its own distinct clinical signature, its own treatment approach, and — critically — it often signals the presence of psoriatic arthritis that needs systemic treatment to prevent joint destruction. Understanding nail psoriasis properly can change the trajectory of a patient’s joint health, not just the appearance of their nails.

What Is Nail Psoriasis

Nail psoriasis is an inflammatory condition of the nail unit driven by the same immune dysregulation — overactive T-cells producing excess IL-17 and TNF-alpha — that drives psoriatic skin plaques. The nail matrix, nail bed, hyponychium, and nail folds can all be involved, each producing distinct clinical changes. Nail involvement in psoriasis is not just cosmetic: the presence and severity of nail disease correlates strongly with psoriatic arthritis activity, and nail disease itself can be debilitating — thick, separated, or crumbling nails cause pain, difficulty with daily tasks, and significant psychological distress.

The Nail Psoriasis Severity Index (NAPSI) scores nails on a 0–8 scale based on matrix and nail bed involvement. A NAPSI score above 14 (summing all 10 nails) correlates with higher psoriatic arthritis burden and typically warrants systemic treatment discussion with a rheumatologist or dermatologist. In our practice, we assess NAPSI scores and coordinate with our patients’ dermatology and rheumatology teams for systemic management decisions.

Clinical Signs and Diagnosis

Nail psoriasis produces a distinctive constellation of changes that, taken together, are highly specific for the diagnosis. The pattern and combination of changes provides the clinical diagnosis in the majority of cases. Nail biopsy confirms the diagnosis when clinical uncertainty remains.

Diagnosis is clinical in most cases — a combination of pitting, oil-drop sign, onycholysis, and subungual hyperkeratosis in a patient with known or suspected psoriasis is highly specific. When the diagnosis is unclear, nail biopsy from the matrix zone demonstrates the characteristic psoriasiform epidermal changes with neutrophilic infiltration (Munro microabscesses) and parakeratosis. Importantly, fungal culture should be performed in any thickened, discolored psoriatic nail — concurrent onychomycosis (called “associated onychomycosis”) is present in 4–27% of nail psoriasis cases and requires concurrent antifungal treatment.

Nail Psoriasis vs. Fungal Infection: How to Tell Them Apart

This distinction is clinically critical and frequently missed. The table below highlights the key differentiating features that guide our diagnosis in clinic. When doubt remains, culture is mandatory — treating fungus with psoriasis medications or psoriasis with antifungals wastes months of the patient’s time and allows the correct condition to worsen.

Treatment Options

Nail psoriasis treatment is stratified by disease severity, the presence of systemic psoriasis or psoriatic arthritis, and patient preference. Treatment decisions for systemic therapy are made collaboratively with dermatology and rheumatology — the podiatrist’s role is local nail treatment, accurate diagnosis, and appropriate referral coordination.

Topical Therapies (Mild Disease)

For mild nail psoriasis (few nails, predominantly hyperkeratosis or onycholysis without matrix involvement), topical treatments applied to the nail folds and hyponychium are first-line. Ultra-potent topical corticosteroids (clobetasol 0.05% solution or gel) applied to the proximal nail fold penetrate to the matrix and reduce pitting and surface irregularity. Calcipotriol (vitamin D analogue) applied to the nail bed reduces subungual hyperkeratosis and onycholysis. Tazarotene (0.1% gel) applied under occlusion to the nail plate reduces pitting. Compliance is the main challenge — these treatments must be applied consistently for 3–6 months before significant improvement is seen. Nail trimming and debridement of subungual hyperkeratosis improves topical penetration and comfort.

Intralesional Corticosteroid Injections (Moderate Disease)

Intralesional triamcinolone acetonide (10 mg/mL) injected into the nail matrix via the proximal nail fold is the most effective local treatment for matrix-driven signs (pitting, leukonychia, nail crumbling). In our practice, we use a 30-gauge needle and inject at the 3 and 9 o’clock positions of the proximal fold under local anesthesia. Patients typically notice nail surface improvement within 8–12 weeks as the treated matrix zone grows out. Injections are repeated every 6–8 weeks. The main limitation is pain (even with anesthesia, matrix injections are uncomfortable) and the risk of nail matrix atrophy with excessive treatment.

Systemic and Biologic Therapies (Moderate-to-Severe Disease)

Systemic therapy is indicated when nail psoriasis is extensive, severely impairs function, is associated with psoriatic arthritis, or has failed local measures. Methotrexate and cyclosporine have modest evidence for nail psoriasis and are limited by side-effect profiles. Biologic therapies have transformed nail psoriasis treatment — TNF inhibitors (adalimumab, etanercept), IL-17 inhibitors (secukinumab, ixekizumab), and IL-23 inhibitors (guselkumab, risankizumab) all achieve high rates of complete or near-complete nail clearance. IL-17 and IL-23 inhibitors produce the most robust nail-specific outcomes: NAPSI scores improve by 70–85% in clinical trials, with many patients achieving complete nail clearance by week 24–52. These medications are prescribed and monitored by dermatology or rheumatology; we coordinate with those teams and manage the local podiatric component.

Nail Avulsion for Symptomatic Relief

When a severely thickened, painful psoriatic toenail is limiting ambulation or footwear use, nail avulsion under local anesthesia provides immediate relief. We do not perform matrixectomy for psoriatic nails (permanent nail removal) because the matrix pathology is immunologic, not mechanical — and the new nail will regrow with psoriatic changes anyway unless systemic disease is controlled. Avulsion is a bridge to comfort while systemic treatment takes effect.

Red Flags: When to Seek Prompt Care

Most Common Mistake with Nail Psoriasis

The most common mistake is treating nail psoriasis as onychomycosis. In our practice, we see patients routinely who’ve had yellow, thickened, separated toenails for years and have been through multiple courses of terbinafine — with no improvement — because their provider never cultured the nail to confirm the diagnosis. The characteristic pitting and oil-drop sign of nail psoriasis are not present in fungal infections; they’re diagnostic when you know to look for them. The second major mistake is treating only the nails while ignoring the systemic disease. Nail psoriasis — particularly dactylitis and nail disease in the absence of skin involvement — is one of the strongest predictors of psoriatic arthritis. Patients with nail psoriasis and any joint symptoms need rheumatology referral, not just a nail treatment.

In-Office Treatment at Balance Foot & Ankle

At Balance Foot & Ankle, we perform NAPSI scoring, PCR-based fungal culture to rule out concurrent onychomycosis, intralesional triamcinolone nail matrix injections, nail debridement, and nail avulsion for symptomatic relief. We coordinate with your dermatologist or rheumatologist for systemic biologic therapy decisions. Dr. Tom Biernacki sees nail psoriasis patients regularly at our Howell and Bloomfield Hills clinics. Call (810) 206-1402 or book online for same-day evaluation.

Frequently Asked Questions

Can nail psoriasis be cured?

Nail psoriasis cannot be permanently cured, but it can be effectively controlled — including complete nail clearance — with appropriate treatment. IL-17 and IL-23 biologic therapies achieve 70–85% NAPSI score improvement, with many patients reaching near-complete nail clearance. Local treatments (intralesional injections, topicals) provide sustained improvement with continued use. Nails relapse when treatment is stopped.

How long does nail psoriasis treatment take to work?

Topical therapies require 3–6 months of consistent use before significant improvement, as the treated nail matrix zone must grow out. Intralesional injections show improvement at 8–12 weeks. Biologic therapies produce measurable NAPSI improvement by weeks 12–24, with maximum response at 52 weeks. Complete nail clearance typically takes 9–12 months from initiation of effective systemic therapy.

Is nail psoriasis the same as toenail fungus?

No. They can look similar (thickening, discoloration, separation) but have completely different causes and treatments. Nail psoriasis is an autoimmune inflammatory condition; onychomycosis is a fungal infection. Key distinguishing features of psoriasis: nail pitting, oil-drop discoloration, and association with psoriatic skin or joint disease. Fungal culture is negative in nail psoriasis. Antifungals don’t treat psoriasis.

When should I see a podiatrist for nail psoriasis?

See a podiatrist if your nails are painful, limiting footwear use or walking, or if you’ve been treating with antifungals without improvement. A podiatrist can perform nail culture to confirm the diagnosis, provide local injections, and coordinate with your dermatologist or rheumatologist for systemic treatment. Balance Foot & Ankle offers same-day appointments — call (810) 206-1402.

Does insurance cover nail psoriasis treatment?

Yes. Podiatric evaluation, nail biopsy, and fungal culture are covered by most plans. Intralesional injections and nail procedures are covered when medically indicated. Biologic therapies typically require prior authorization and documented failure of conventional systemic therapy. Our team handles insurance verification and authorization paperwork.

Sources

1. Rich P, Scher RK. “Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis.” Journal of the American Academy of Dermatology. 2003;49(2):206–212.
2. Griffiths CEM, et al. “Psoriasis.” Lancet. 2021;397(10281):1301–1315.
3. van der Velden HMJ, et al. “Diagnosis and management of nail psoriasis.” Dermatologic Clinics. 2022;40(3):311–324.
4. Schons KRR, et al. “Nail psoriasis: a review of the literature including the associated comorbidities and the available treatments.” Anais Brasileiros de Dermatologia. 2014;89(2):312–317.
5. Blauvelt A, et al. “Secukinumab nail clearance in nail psoriasis.” New England Journal of Medicine. 2015;373(14):1318–1328.
6. Gordon KB, et al. “Guselkumab for plaque psoriasis and nail disease.” Journal of the American Academy of Dermatology. 2025;92(4):814–821.

Frequently Asked Questions